Back to search

Article

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer

2024-02-22

Abstract excerpt

As colorectal cancer (CRC) remains a leading cause of cancer-related death, identifying therapeutic targets and approaches is essential to improve patient outcomes. The EGFR ligand epiregulin (EREG) is highly expressed in RAS wildtype and mutant CRC with minimal expression in normal tissues, making it an attractive target for antibody-drug conjugate (ADC) development. In this study, we produced and purified an ERE...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
34d85294-5ec8-5778-ba28-5b7f5e098270
DOI
10.1101/2024.02.20.581056
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerDOI 10.1101/2024.02.20.581056
An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancerSemantic proximity
Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer modelsSemantic proximity
Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.Semantic proximity
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificitySemantic proximity
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.Semantic proximity
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancerSemantic proximity
Novel COX-2–Targeted Nanobodies for Molecular Endoscopic Imaging of Colorectal AdenomasSemantic proximity
Multiplexed Targeting of Barrett’s Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex VivoSemantic proximity
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.Semantic proximity
LGR5 targeting molecules as therapeutic agents for multiple cancer typesSemantic proximity
Select a neighboring publication to make it the new centre.